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ABSTRACT 
One of the most suitable and most used biodegradable polymers in particulate drug delivery is Polycaprolactone. This could be 
attributed to its several important characteristics including its low degradation rate, high permeability and low toxicity. In this study, 
Polycaprolactone microspheres loaded with the antifungal agent Amphotericin B were synthesized by means of the solvent 
evaporation method. The prepared microspheres had homogeneous particle sizes between 110 and 125 µm. they also showed a 
porous structure and a spherical profile. Satisfactory drug encapsulation percentages and drug loading values were obtained. They 
varied from 28 to 61 % and 0.22 to 1.13 % respectively. These observed results could be related to the properties of both drug and 
polymer such as hydrophobicity and solubility in organic solvents. In addition, the low degradation activity of the polymer 
Polycaprolactone had a direct impact on the release rate of Amphotericin B, yielding prolonged and slow release profiles for most of 
the formulations. Finally, Infrared study revealed that the method used for encapsulation of Amphotericin B with Polycaprolactone 
did not have any negative effect on the integrity and stability of the drug.       
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INTRODUCTION 
Drug Delivery Systems using biodegradable polymeric 
particles have become one of the most important topics 
in the pharmaceutical and medical work. They present 
many advantages including sustained delivery of drugs, 
their localized delivery, and their stabilization in order 
to avoid their major side effects. Biodegradable and 
biocompatible polyesters such as Polylactic acid (PLA), 
poly(lactic-co-glycolic acid) (PLGA), polycaprolactone 
and their copolymers are considered essential materials 
for successful and efficient drug delivery systems 
1-4
. 
Polycaprolactone (PCL) is very suitable for controlled 
delivery due to its high permeability to a wide range of 
drugs, non-toxicity, and low degradation rate. PCL is a 
hydrophobic and semi-crystalline polymer
1-5
. Its good 
solubility in many solvents and its exceptional blend-
compatibility has enabled it to be used extensively in 
several medical applications. This has a positive effect 
on the drug release rate 
6, 7
. These advantages have made 
it widely used in preparation of polymeric 
microparticles and nanoparticles, scaffolds and tissues 
1-
6
. 
Degradation of PCL in comparison to the other 
polyesters is very slow, which is mainly needed for 
long-term delivery extending over a period of more than 
one year. In addition, the non-toxic products from its 
biodegradation also contribute in being favorable in 
delivery vehicles 
8, 9
. Several drugs or biological 
molecules have been encapsulated into PCL 
microspheres or nanospheres such as Nifedipine, 
Indomethacin, Taxol, antigens, hormones, steroids, etc. 
5-10
. 
In previous studies, PCL nanospheres loaded with the 
antifungal agent Amphotericin B (AmB) were prepared 
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using the solvent displacement method 
11
.  In this 
project, AmB will be encapsulated into PCL 
microspheres by means of oil-in-water solvent 
evaporation technique. Preparation of microspheres with 
this technique is very convenient in yielding particles 
with a large surface area to volume ratio. This makes 
them very efficient in drug delivery and targeting, 
mainly in cases where extended and prolonged release is 
required 
12, 13
. 
MATERIALS AND METHODS 
Chemicals used: The polymer, PCL (average MW 
80,000), AmB, the surfactant Tween 80, and Phosphate 
Buffered Saline (PBS) (0.2 M, pH 7.4) are purchased 
from Sigma-Aldrich, Chemie, Germany. The solvents 
dichloromethane (DCM) and Methanol (MeOH) are of 
analytical grade. 
Formulation of Microspheres: o/w emulsion solvent 
evaporation technique is used for the formulation of 
AmB-loaded PCL microspheres. It consists of mixing 
the organic polymeric phase with an aqueous phase. 
Specific drug mass is dissolved in 14:6 ml DCM/MeOH 
containing 500 mg polymer, forming the organic phase. 
This mixture was added into 250 ml aqueous phase 
containing 1% w/v Tween 80. The whole combination is 
stirred for 6 hours at 1400 rpm over a mechanical stirrer 
(MSP-1 Digital Overhead Stirrer, Jeiotech, Korea). The 
resulting solution is filtered to collect the obtained 
microspheres. These are then washed with distilled 
water and MeOH, and oven dried.  
Characterization: 
1. Particle size and morphology: A Laser 
Diffraction Granulometer (LA950V2, Horiba Ltd., 
France) is used to determine the size of microspheres. A 
quantity of microspheres is suspended in water, with 
Tween 80 used as dispersant. The average particle size 
is measured in micrometers.  
The morphological characteristics of microspheres are 
examined by Scanning Electron Microscopy (SEM) 
(LYRA3 XMU, TESCAN, Czech Republic). 
Microspheres are fixed to a carbon conductive tape. A 
coating of 10 nm of Platinum is applied using a sputter 
coater. 
2. Drug Encapsulation (%DE) and Drug 
Loading (%DL): Microspheres are dissolved in 7/3 ml 
DCM/MeOH and the drug content of each formulation 
is measured using a UV/Vis Spectrophotometer 
(Microplate Spectrophotometer, Epoch Biotek, USA) at 
409 nm. %DE and %DL are calculated as follows: 
%DE = 
introduced drug of mass
edencapsulat drug of mass
*100  
%DL = 
esmicrospher of mass
esmicrospherin  drug of mass
*100  
3. In vitro drug release study: The In vitro 
release study is carried out in PBS solution (0.2 M, pH 
7.4). 25 mg microspheres are introduced in small vials 
containing 25 ml PBS, used as release medium, and 
maintained at 37°C. At specific time intervals, 5 ml of 
the release medium is withdrawn and replaced with 
fresh solution. It is then evaluated for its drug content at 
409 nm. 
4. Fourier Transform-Infrared study (FT-IR): 
FT-IR spectra of AmB, PCL blank microspheres and 
AmB-loaded microspheres are determined using a FT-
IR spectrometer (Frontier, Perkin Elmer, USA) in order 
to investigate the possible chemical interactions between 
the drugs and the polymer matrix. 
RESULTS AND DISCUSSION 
The solvent evaporation is one of the most common and 
successful methods for drug encapsulation. It presents 
many positive returns including the ease of its 
application and the reproducibility of its results. Also, a 
major factor for its effectiveness is in obtaining good 
encapsulation values for both hydrophobic as well as 
hydrophilic drugs 
14
.  
Particle Size and Morphology:  
AmB-loaded PCL Microspheres were homogeneous in 
size ranging between 110 µm and 125 µm (Table 1). As 
for the surface morphology of microspheres after 
examination by SEM, Figure 1 shows that they 
exhibited a spherical profile with a smooth and porous 
structure. 
 
 
Figure 1: SEM photograph of the prepared 
microspheres at (a) x 100 and (b) x1000 
magnifications 
Drug Encapsulation (%DE) and Drug Loading 
(%DL): 
Good values for drug encapsulation and drug loading 
were obtained. Since AmB is hydrophobic in character, 
(a) 
(b) 
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it tends to remain in the organic polymer phase, leading 
to low loss of the drug into the aqueous phase and the 
satisfactory encapsulation values. In addition, using 
dichloromethane as major solvent in the 
microencapsulation procedure is advantageous 
compared to other organic solvents as Chloroform or 
Benzene. Dichloromethane has a high solubility in water 
which allows fast mass-transfer between the dispersed 
and continuous phases. This leads to fast precipitation of 
the polymer and good drug entrapment 
15
.  
Regarding drug loading values, as more drug quantity is 
introduced, it is being more included into the polymeric 
microparticles. This explains the increasing %DL from 
0.2 to 1% as the drug mass increases from 10 mg to 75 
mg. In a previous study, the antifungal drug AmB was 
encapsulated into poly (DL-lactide-co-caprolactone) 
microspheres under the same conditions. Results 
showed lower drug loading compared to PCL. This 
could be explained by the more hydrophobic character 
of the polymer which enables it to retain more drug 
quantity 
16
.  
 
Table 1: %DE, %DL and particle size of the prepared formulations 
Formulation code Drug Introduced (mg) %DE %DL size (µm) 
A1 10 55 0.22 114 
A2 20 61 0.48 115 
A3 35 46 0.63 110 
A4 50 36 0.71 126 
A5 75 31 1.08 126 
A6 100 28 1.13 123 
 
In Vitro Release: 
Conforming to the low degradation and crystallinity of 
PCL among known polyesters used in targeted delivery, 
water penetration into PCL polymeric matrices is lower. 
This leads to drug release by diffusion and not by 
polymer degradation 
17
. 
 
Figure 2: Variation of the release time according to 
%DL of AmB-loaded formulations 
Figure 2 shows the release time of the different %DL of 
the prepared formulations. The release rate becomes 
slower at higher %DL to reach a maximum of one 
month for formulation A5. In fact, at higher loadings, 
the chances of drug particles inside the polymer matrix 
to contact each other are high. This causes the formation 
of aggregates that need more time to dissolve, and thus 
more time for the drug to be released 
18
. 
Figure 3 presents the drug release profile of the 
available drug formulations. It is characterized by a 
burst release between days 5 and 10 where 30-40% of 
AmB was released. This is shown in particular for 
formulations with lower % DL. The initial burst could 
be due to the dissolution of drug molecules that are 
present at the surface of microspheres 
14, 19
. 
In opposite, an extended prolonged release was shown 
for the other formulations and required one month to go 
to completion. Since AmB is a hydrophobic drug, it is 
retained inside the core of the polymeric matrix after 
encapsulation not near the surface of particles as in the 
case of hydrophilic drugs. As a result, it requires more 
time to diffuse to the aqueous buffer medium and to be 
released 
8-10, 15
.  
Besides, the polymer PCL is more hydrophobic than 
other polyesters. This contributes in making its 
degradation very slow in aqueous medium, and in turn 
suitable for controlled and extended drug release 
9, 10, 14-
17
.
 
 
Figure 3: Drug release profile of the prepared AmB-loaded formulations 
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FT-IR Analysis: 
Table 2: Characteristics Peaks of AmB and PCL 
4, 16, 
20, 21
 
 Band (cm
-1
) Type of bond 
AmB 
1560 -C=C alkene 
2900-3000 -C-H stretching alkane 
3300-3400 
-OH alcohol 
-NH2 amine 
PCL 
1160 -C-O ester 
1365 -C-H banding alkane 
1720 -C=O Ketone 
2900-3000 -C-H bending alkane 
 
FT-IR study was carried out in order to identify the 
purity and chemical stability of drug and polymer 
following the microencapsulation process. Table 2 
shows the characteristic peaks of AmB and PCL. 
Figures 3, 4 and 5 illustrate the spectra recorded on the 
IR spectrometer. Comparison of bands among the three 
spectra showed no significant large shift or deviation in 
the spectra of the drug and polymer when formulated 
into microspheres. All the characteristic peaks of AmB 
and PCL are showing in the spectrum of AmB-loaded 
microspheres (Table 2). These results indicate that the 
solvent evaporation was efficient in encapsulating the 
drug into PCL microspheres while remaining stable and 
intact. 
   
Figure 4: FT-IR spectrum of AmB 
 
Figure 5: FT-IR spectrum of PCL blank microspheres  
 
Figure 6: FT-IR spectrum of AmB-loaded microspheres 
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CONCLUSION 
In this project, the biodegradable polymer 
Polycaprolactone was used for the encapsulation of the 
antifungal agent Amphotericin B into porous and 
spherical particles with homogeneous sizes. Several 
samples were prepared by fixing the polymer quantity 
and modifying the drug mass. Drug encapsulation and 
loading percentages were reasonable, ranging between 
28 and 61% and 0.22 and 1.13% respectively. The 
release rate was slow for the most of the formulations, 
and was directly affected by the degradation rate of the 
polymer and hydrophobicity of both drug and polymer. 
Finally, the drug-polymer compatibility study by FT-IR 
revealed their stability with no change in any chemical 
composition. 
Conflict of Interest 
All contributing authors declare no conflicts of interest. 
 
REFERENCES 
1- Dash TK, Konkimalla VB, Poly-є-caprolactone based 
formulations for drug delivery and tissue engineering: a 
review, Journal of Controlled Release, 2012; 158(1):15-33. 
2- Yammine P, Maarawi T, Moussa D, Abdel-Massih R, Kassab 
R, Effects of different surfactants on Indomethacin 
microspheres formulations, Journal of Advances in Chemistry, 
2015; 11(4):3453-3462. 
3- Ferreira SI,  Bettencourt AF, Gonçalves MD, Kasper S, 
Bétrisey B, Kikhney J, Moter A, Trampuz A, Almeida AJ, 
Activity of Daptomycin- and Vancomycin-loaded poly-
epsilon-caprolactone microparticles against mature 
staphylococcal biofilms, International Journal of 
Nanomedicine, 2015; 10(1):451-4366. 
4- Natarajan V, Krithica N, Madhan B, Sehgal PK, Formulation 
and evaluation of Quercitin polycaprolactone microspheres for 
the treatment of rheumatoid arthritis, Journal of 
Pharmaceutical Sciences, 2011; 100(1):195-205. 
5- Woodruff MA, Hutmacher DW, The return of a forgotten 
polymer- polycaprolactone in the 21
st
 century, Progress in 
Polymer Science, 2010; 35(10):1217-1256. 
6- Miladi K, Ibraheem D, Iqbal M, Sfar S, Fessi H, Elaissari A, 
Particles from preformed polymers as carriers for drug 
delivery, EXCLI Journal, 2014; 13:28-57. 
7- Dhanaraju M, Sathyyamoorthy N, Sundar V, Preparation of 
polycaprolactone microspheres containing Etoposide by 
solvent evaporation method, Asian Journal of Pharmaceutical 
Science, 2010; 5(3):114-122. 
8- Behara AK, Barik BB, Joshi S, Polycaprolactone based 
microspheres and nanospheres: a review, FS Journal of 
Pharmacy Research, 2012; 1(2):38-45. 
9- Aydin O, Aydin B, Tezcaner A, Keskin D, Study of 
physicochemical structure and in vitro release behaviors of 
Doxycycline-loaded PCL microspheres, Journal of Applied 
Polymer Science, 2015; 132(14):41768 (1-13). 
10- Mondal D, Griffith M, Venkatraman S, Polycaprolactone-
based biomaterials for tissue engineering and drug delivery: 
current scenario and challenges, International Journal of 
Polymeric Materials and Polymeric Biomaterials, 2016; 
65(5):255-265. 
11- Aminu N, Baboota S, Pramod K, Singh M, Dang S, Ansari 
SH, Sahni JK, Ali J, Development and evaluation of Triclosan 
loaded poly-ε-caprolactone nanoparticulate system for the 
treatment of periodontal infections, Journal of Nanoparticle 
Research, 2013; 15(11):1-15. 
12- Wang X, Wang Y, Wei K, Zhao N, Zhang S, Chen J, Drug 
distribution within poly(ε-caprolactone) microspheres and in 
vitro release, Journal of Materials Processing Technology, 
2009; 209(1):348-354. 
13- Dash T, Koncimalla V, Polymeric modification and its 
implication in drug delivery: poly(ε-caprolactone as a model 
polymer, Molecular Pharmaceutics, 2012; 9(9):2365-2379. 
14- Waknis V, Jonnalagadda S, Novel poly-dl-lactide-
polycaprolactone copolymer based flexible drug delivery 
system for sustained release of Ciprofloxacin, Drug Delivery, 
2011; 18(4):236-245. 
15-  Jelvehgari M, Valizadi H, Rezapour M, Nokhodchi A, 
Control of encapsulation efficiency in polymeric microparticle 
system of Tolmetin, Pharmaceutical Development and 
Technology, 2010; 15(1):71-79. 
16- Yammine P, Kassab R, Moussa D, Moussa R, Poly(DL-
lactide-co-caprolactone) as drug carrier for antifungal drug 
Amphotericin B, 2012; 4(4):477-483. 
17- Pepic D, Nikolic MS, Grujic S, Lausevic M, Djonlagic J, 
Release behaviour of Carbamazepine-loaded poly(ɛ-
caprolactone)/ poly(ethylene oxide) microspheres, Journal of 
Microencapsulation, 2013; 30(2):151-160. 
18- Kassab R, Yammine P, Moussa D, Safi N, A comparative 
study of Doxycycline and Tetracycline polymeric 
microspheres, International Journal of Pharmaceutical 
Sciences and Research, 2014; 5(6):2452-2457. 
19- Iqbal S, Rashid MH, Arbab AS, Khan M, Encapsulation of 
anticancer drugs (5-Fluorouracil and Paclitaxel) into 
polycaprolactone nanofibers and in vitro testing for sustained 
and targeted therapy, Journal of Biomedical Nanotechnology, 
2017; 13(4):355-366. 
20- Angra P, Oettinger C, Pai SB, D’Souza MJ, Amphotericin B 
microspheres: a therapeutic approach to minimize toxicity 
while maintaining antifungal efficacy, Journal of 
Microencapsulation, 2009; 26(7):580-587. 
21- Das S, Suresh PK, Nanosuspension: a new vehicle for the 
improvement of the delivery of drugs to the ocular surface: 
application to Amphotericin B, Nanomedicine: 
Nanotechnology, Biology, and Medicine, 2011; 7(2):242–247. 
 
